Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Estrogen Receptor Positive HER2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Large-scale testing (Phase 3)Looking for participantsNCT07647328
What this trial is testing

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 150
Early research (Phase 1)Study completedNCT02248090
What this trial is testing

AZD9496 First Time in Patients Ascending Dose Study

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 45
Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Testing effectiveness (Phase 2)Study completedNCT02007512
What this trial is testing

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 247
Testing effectiveness (Phase 2)Study completedNCT02756364
What this trial is testing

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Who this might be right for
Breast Neoplasms
Calithera Biosciences, Inc 141
Testing effectiveness (Phase 2)Study completedNCT00856492
What this trial is testing

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 215
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Testing effectiveness (Phase 2)Looking for participantsNCT07427394
What this trial is testing

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 24
Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Early research (Phase 1)Active Not RecruitingNCT04288089
What this trial is testing

H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Who this might be right for
Receptors, EstrogenGenes, Erbb-2Breast Neoplasms
Eisai Inc. 31
Early research (Phase 1)Ended earlyNCT02384746
What this trial is testing

Phase I Study of the Combination of MLN9708 and Fulvestrant

Who this might be right for
Breast Cancer
Dartmouth-Hitchcock Medical Center 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Not applicableEnded earlyNCT06126003
What this trial is testing

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Who this might be right for
Breast Cancer
BioCorteX Inc 2
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Early research (Phase 1)Study completedNCT03725436
What this trial is testing

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 28
Early research (Phase 1)Ended earlyNCT04504331
What this trial is testing

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Jennifer Lee Caswell-Jin 4
Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Next Page